Omalizumab facilitates rapid oral desensitization for peanut allergy

BACKGROUND: Peanut oral immunotherapy (OIT) is a promising approach to peanut allergy but reactions are frequent and some patients cannot be desensitized. The anti-IgE medication omalizumab (Xolair) may allow more rapid peanut updosing and decrease reactions. OBJECTIVE: To evaluate if omalizumab fac...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Allergy Clin Immunol
Main Authors: MacGinnitie, Andrew J., Rachid, Rima, Gragg, Hana, Little, Sara V, Lakin, Paul, Cianferoni, Antonella, Heimall, Jennifer, Makhija, Melanie, Robison, Rachel, Chinthrajah, R. Sharon, Lee, John, Lebovidge, Jennifer, Dominguez, Tina, Rooney, Courtney, Lewis, Megan Ott, Koss, Jennifer, Burke-Roberts, Elizabeth, Chin, Kimberly, Logvinenko, Tanya, Pongracic, Jacqueline A., Umetsu, Dale T., Spergel, Jonathan, Nadeau, Kari C., Schneider, Lynda C.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5369605/
https://ncbi.nlm.nih.gov/pubmed/27609658
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jaci.2016.08.010
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados